Alnylam Pharmaceuticals, Inc. (ALNY) News
Track canonical SquawkNews coverage tagged to ALNY, Alnylam Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about nasdaq, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 33 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Jefferies raises Jefferies Alnylam price target to $260
Jefferies raised its price target on Alnylam Pharmaceuticals to $260.00 per share from $230.00 and maintained a Hold rating, according to Benzinga/TradingView News.
EQUITY | Sep 08, 2026, 03:48 PM UTC
M
ALNY optimism on AMVUTTRA growth, reduced competition and pipeline progress
TradingView News cites strong AMVUTTRA cardiomyopathy launch-driven revenue and first-line market growth. It also points to extended tafamidis exclusivity, a failed rival trial, international expansion, and pipeline prog
EQUITY | Sep 08, 2026, 02:21 PM UTC
L
ALNY: AMVUTTRA’s first-line growth, strong data, and pipeline advances drive optimism for future expansion
AMVUTTRA’s strong commercial growth is driven by first-line adoption, robust clinical data, and broad access, with ex-U.S. expansion expected to accelerate after initial pricing adjustments. Competitive and pricing risks
EQUITY | Sep 08, 2026, 01:45 PM UTC
L
Stephens watchlist flags potential S&P Dow Jones September index changes
Stephens identified companies that could be added to, moved between, or removed from S&P Dow Jones Indices in the third-quarter rebalance after the close on Friday, September 18.
EQUITY | Sep 03, 2026, 04:05 PM UTC
L
Alnylam to webcast presentations at upcoming September investor conferences
Alnylam Pharmaceuticals said management will present company overviews at upcoming September investor conferences, with live audio webcasts available on the Investors section of its website.
EQUITY | Sep 02, 2026, 12:01 PM UTC
L
HC Wainwright maintains Alnylam price target at $455
HC Wainwright & Co. maintained its Alnylam Pharmaceuticals price target of $455.00 per share, according to Benzinga/TradingView News.
EQUITY | Sep 02, 2026, 10:28 AM UTC
H
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Tre
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
GEOPOLITICS | Aug 30, 2026, 12:23 PM UTC
L
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
EQUITY | Aug 28, 2026, 09:19 PM UTC
H
Alnylam cuts 2026 Amvuttra revenue guidance
Alnylam Pharmaceuticals cuts full-year 2026 revenue guidance for its Amvuttra franchise after early demand was inflated by a rush of pent-up patients.
EARNINGS | Aug 20, 2026, 04:03 PM UTC
L
BMO initiates ALNY at Outperform with $318 target
BMO assigns ALNY an Outperform rating and a $318 price target.
EQUITY | Aug 19, 2026, 11:48 AM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
H
Stocks Rise After Upgrades, Initiations
Select stocks gain after upgrades and initiations
EQUITY | Aug 03, 2026, 11:52 AM UTC
H
ALNY Upgraded to Strong Buy at Raymond James
ALNY upgraded with $420 price target
EQUITY | Aug 03, 2026, 11:48 AM UTC
H
Alnylam Selloff Creates Entry Point
Alnylam selloff creates attractive entry point
EQUITY | Aug 03, 2026, 11:13 AM UTC
H
Alnylam Maintains Outperform
Alnylam price target lowered to $350
EQUITY | Jul 31, 2026, 12:52 PM UTC
H
Alnylam PT Cut to $350 at RBC
RBC cuts Alnylam price target
EQUITY | Jul 31, 2026, 12:01 PM UTC
H
ALNY Reiterate Buy and lowering PT from $444 to $318 after Q2 results @ Stifel
ALNY Reiterate Buy and lowering PT from $444 to $318 after Q2 results @ Stifel
EARNINGS | Jul 31, 2026, 11:37 AM UTC
H
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY ) stock plunged on Thursday after the company lowered its fiscal 2026 guidance. The company reported second-quarter adjusted earnings of $1.84 per share, beating the consensus o
EARNINGS | Jul 30, 2026, 06:37 PM UTC
H
ALNY lows -30% after results
ALNY lows -30% after results
EARNINGS | Jul 30, 2026, 06:08 PM UTC
H
Stock Market Today: Microsoft Ignites Chip Rebound as SanDisk Jumps 24%
U.S. equities clawed back Wednesday’s post-Fed losses by midday Thursday, with a blowout cloud print from Microsoft Corp. (NASDAQ: MSFT ) reviving the artificial intelligence trade and dragging beaten-down semiconductor
EARNINGS | Jul 30, 2026, 05:29 PM UTC
H
Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Thursday. The Dow traded up 0.40% to 51,801.63 while the NASDAQ surged 2.08% to 24,952.56. The S&P 500 also rose,
EARNINGS | Jul 30, 2026, 04:02 PM UTC
L
ALNY -23.2%, CROX -12.3%, FICO -10.8%, H -9.1%, CVNA -9.8%, WWD -9.8%, TW -9.8%, NXLH -9.5%, META -9.6%, CHRW -10%, LHX -8.3%, FTAI -8%, MO
ALNY -23.2%, CROX -12.3%, FICO -10.8%, H -9.1%, CVNA -9.8%, WWD -9.8%, TW -9.8%, NXLH -9.5%, META -9.6%, CHRW -10%, LHX -8.3%, FTAI -8%, MO -7.3%, WDAY -8%, CRS -7.6%, OMC -6.1%, TEAM -7.4%, INTU -6.1%, HUBS -6%, HPQ -6%
EQUITY | Jul 30, 2026, 01:38 PM UTC
H
Alnylam Pharmaceuticals Posts Q2 Adjusted EPS $1.84
Alnylam beats Q2 adjusted EPS estimate
EARNINGS | Jul 30, 2026, 01:15 PM UTC
H
Alnylam trims 2026 sales forecast
Alnylam cuts 2026 product sales forecast
EARNINGS | Jul 30, 2026, 12:37 PM UTC
H
US Stocks Rise After Earnings
US stocks gain after earnings reports
EARNINGS | Jul 30, 2026, 12:26 PM UTC
H
Alnylam Pharmaceuticals Lowers FY2026 Sales Guidance from $5.300B-$5.800B to $5.275B-$5.725B vs $5.580B Est
Alnylam Pharmaceuticals (NASDAQ: ALNY ) lowers FY2026 sales outlook from $5.300 billion-$5.800 billion to $5.275 billion-$5.725 billion vs $5.580 billion estimate.
EARNINGS | Jul 30, 2026, 12:03 PM UTC
H
ALNY Alnylam Pharmaceuticals RESULTS: Q2, Q2 ADJ Net Income $251.801M, Q2 Operating Income $231.441M, Q2 ADJ Operating Income $318.066M, Q2
ALNY Alnylam Pharmaceuticals RESULTS: Q2, Q2 ADJ Net Income $251.801M, Q2 Operating Income $231.441M, Q2 ADJ Operating Income $318.066M, Q2 ADJ EPS $1.84 vs. EST $1.55, Q2 Net Income $164.494M, Q2 REV $1,290.948M vs. EST
EARNINGS | Jul 30, 2026, 12:02 PM UTC
H
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bl
earnings calendar: • earnings before the open: abev adt aep ag agco agio algm alny amcx amrx aos apd apg avy bax bc bdc bdrbf bfly bgc bi bldr bmy bud ccc cfr chkp ci cmco cnk cnx crh crox crs csw cwt dar dfin dsx dtm ee
EARNINGS | Jul 30, 2026, 11:18 AM UTC
H
Implied EPS movers for tomorrow AM: MA +/-2.8%, VLO +/-3.9%, AEP +/-4.6%, BMY +/-3.7%, ICE +/-3.4%, REGN +/-4.3%, TT +/-7.2%, EXC +/-4.3%, P
Implied EPS movers for tomorrow AM: MA +/-2.8%, VLO +/-3.9%, AEP +/-4.6%, BMY +/-3.7%, ICE +/-3.4%, REGN +/-4.3%, TT +/-7.2%, EXC +/-4.3%, PWR +/-11.7%, ALNY +/-9.9%, XEL +/-6.3%, MO +/-3.3%, SO +/-2.0%, YUM +/-6.0%, CI
EARNINGS | Jul 29, 2026, 06:05 PM UTC
H
ALNY Earnings pre-market tomorrow: qtr EPS est $1.55 (high $2.28/low $1.00), 30-day avg EPS revision -5.6% (5 analyst(s) revised up, 3 down)
ALNY Earnings pre-market tomorrow: qtr EPS est $1.55 (high $2.28/low $1.00), 30-day avg EPS revision -5.6% (5 analyst(s) revised up, 3 down), qtr revs est $1.32B; FY EPS est $7.10, FY revs est $5.58B; short interest 4.32
EARNINGS | Jul 29, 2026, 05:07 PM UTC
H
Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says
() -- Alnylam Pharmaceuticals' (ALNY) Q2 financial results will be important in determining where 2026 revenue will fall within the guidance range and whether management would further refine that guidance, BofA Securitie
EARNINGS | Jul 14, 2026, 02:52 PM UTC
L
ALNY PT reduced from $460 to $410, maintains Buy @ BAML
ALNY PT reduced from $460 to $410, maintains Buy @ BAML
EQUITY | Jul 14, 2026, 12:24 PM UTC
H
Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Shares of Ultra Clean Holdings Inc (NASDAQ: UCTT ) rose sharply in pre-market trading after the company announced the appointment of Michael Keogh as CFO. The company appoints Michael Keogh as CFO, effective Aug. 25, suc
EARNINGS | Jul 09, 2026, 08:53 AM UTC